FDA Takes Efforts to Protect Patients From Potentially Harmful Compounded Drugs Through Finalizing Insanitary Conditions Guidance
WASHINGTON, D.C. — Protecting patients from exposure to poor quality compounded drugs is a fundamental part of the U.S. Food and Drug Administration’s drug compounding program. While compounded drugs can …
Read More